Instead of acting in a manner dependent on the HIF-induced proangiogenic effect, FTO targets the glutamine transporter SLC1A5, modulating metabolic reprogramming and maintaining the survival of VHL-deficient tumour cells [122]. The gene discussed is FTO; the disease is neoplasm.